Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolapitant for Nausea and Vomiting in Sarcoma Patients Receiving AI Chemotherapy
NCT02732015Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rolapitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2016; status: terminated.
02
Drugs
rolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02732015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732015.